Alumis Inc. (NASDAQ:ALMS - Get Free Report) CEO Martin Babler acquired 15,650 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was bought at an average cost of $6.44 per share, with a total value of $100,786.00. Following the completion of the transaction, the chief executive officer now directly owns 106,454 shares in the company, valued at $685,563.76. The trade was a 17.23 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Alumis Price Performance
Shares of ALMS stock opened at $8.54 on Friday. Alumis Inc. has a 52-week low of $3.18 and a 52-week high of $13.53. The business has a 50-day simple moving average of $5.46 and a 200-day simple moving average of $8.24.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of ALMS. BNP Paribas Financial Markets purchased a new position in shares of Alumis during the 3rd quarter valued at approximately $27,000. Wells Fargo & Company MN grew its position in Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock valued at $69,000 after buying an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Alumis in the fourth quarter valued at $79,000. MetLife Investment Management LLC acquired a new position in shares of Alumis in the third quarter worth about $89,000. Finally, Marshall Wace LLP purchased a new stake in shares of Alumis during the 4th quarter worth about $108,000.
Wall Street Analyst Weigh In
ALMS has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Alumis in a report on Wednesday, March 26th. Oppenheimer began coverage on Alumis in a research note on Thursday, January 30th. They issued an "outperform" rating and a $32.00 target price for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a research note on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $26.00.
Check Out Our Latest Report on ALMS
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
